Oncolytics Biotech (TSX:ONC) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oncolytics Biotech's EBITDA for the three months ended in Dec. 2024 was C$-8.34 Mil. Oncolytics Biotech's Revenue for the three months ended in Dec. 2024 was C$0.00 Mil. Therefore, Oncolytics Biotech's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Oncolytics Biotech EBITDA Margin % Historical Data

The historical data trend for Oncolytics Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech EBITDA Margin % Chart

Oncolytics Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

Get a 7-Day Free Trial

Oncolytics Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Oncolytics Biotech's EBITDA Margin %

For the Biotechnology subindustry, Oncolytics Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Oncolytics Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oncolytics Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-34.558	/	0
	=	%

Oncolytics Biotech's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-8.339	/	0
	=	%

Oncolytics Biotech (TSX:ONC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Oncolytics Biotech EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

ONCY:USA

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Executives